Scholarlink

Introduction <p>Sleep disturbances (SD) are common in chronic liver diseases and neurodegenerative disorders, including Wilson’s disease (WD). However, there is limited evidence regarding improvement in sleep quality following initiation of anti-copper therapy in treatment-naïve WD patients.</p> Methods <p>We performed and evaluated video-polysomnography (vPSG) in six newly diagnosed, treatment-naïve WD patients. All patients underwent overnight vPSG before and after initiation of anti-copper treatment.</p> Results <p>None of the patients reported subjective SD during routine clinical assessment. Objective improvement in sleep efficiency (SE) was observed in five patients, with increases of 6.4%, 7.4%, 17.1%re, 17.3%, and 45.6%, respectively. In three patients, SE normalized (&gt; 90%) after treatment. One patient demonstrated a decline in SE on follow-up (73.5% vs. 67.4%).</p> Conclusions <p>Initiation of anti-copper treatment in newly diagnosed WD patients may lead to improvements in sleep quality, in addition to neurological symptom relief. These preliminary findings warrant confirmation in larger, controlled studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Improvement in sleep following treatment initiation in newly diagnosed, treatment-naïve patients with Wilson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月2日

查看全文
  • Wojciech Jernajczyk,
  • Tomasz Litwin,
  • Agnieszka Antos,
  • Jan P. Bembenek

摘要

Introduction

Sleep disturbances (SD) are common in chronic liver diseases and neurodegenerative disorders, including Wilson’s disease (WD). However, there is limited evidence regarding improvement in sleep quality following initiation of anti-copper therapy in treatment-naïve WD patients.

Methods

We performed and evaluated video-polysomnography (vPSG) in six newly diagnosed, treatment-naïve WD patients. All patients underwent overnight vPSG before and after initiation of anti-copper treatment.

Results

None of the patients reported subjective SD during routine clinical assessment. Objective improvement in sleep efficiency (SE) was observed in five patients, with increases of 6.4%, 7.4%, 17.1%re, 17.3%, and 45.6%, respectively. In three patients, SE normalized (> 90%) after treatment. One patient demonstrated a decline in SE on follow-up (73.5% vs. 67.4%).

Conclusions

Initiation of anti-copper treatment in newly diagnosed WD patients may lead to improvements in sleep quality, in addition to neurological symptom relief. These preliminary findings warrant confirmation in larger, controlled studies.